Spyre Therapeutics, Inc. (SYRE) Stock Price & How to Invest

Spyre Therapeutics (Nasdaq: SYRE) is a clinical-stage biotechnology company building extended half-life antibodies and antibody combinations aimed at inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, plus rheumatic diseases. Its lead programs target the TL1A pathway (SPY002 and SPY072) and complementary mechanisms such as alpha4beta7 (SPY001) and IL-23 (SPY003), engineered for less frequent dosing (potentially quarterly or twice-yearly) than existing biologics like Entyvio. The company has no marketed products and generates no product revenue; its worth is tied to clinical progress and the large addressable IBD market.

As a pre-revenue name, Spyre trades on pipeline expectations rather than fundamentals. A positive Part A readout from the Phase 2 SKYLINE trial in ulcerative colitis, a fully enrolled SKYWAY basket trial in rheumatic diseases, and a queue of roughly six proof-of-concept readouts slated for 2026 have driven the stock sharply higher and pulled in analyst target hikes. The flip side is heavy competition in the TL1A field from far larger players and the usual clinical-trial risk, where a single disappointing data point can reset the valuation.

Spyre is pre-revenue and unprofitable, with a net loss of roughly $149 million over the trailing twelve months (as of July 2026), so the valuation rests entirely on future clinical success. Its programs are mostly early to mid-stage, and Phase 2 results do not guarantee Phase 3 or approval; a single failed readout among the six planned for 2026 could sharply cut the stock. The TL1A space is intensely competitive, with Merck's tulisokibart already reporting pivotal ulcerative colitis data and Roche, Sanofi/Teva, and others racing ahead, meaning Spyre may reach market later than established rivals. The stock is highly volatile (beta near 3), and further equity raises would dilute holders. Any clinical, regulatory, or safety setback carries outsized downside for a company with no product sales.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Spyre Therapeutics, Inc.'s investor relations page or your broker.

• Product revenue (TTM): ~$0 (clinical-stage)
• Net loss (TTM): ~-$149M
• EPS (TTM): ~-$2.17
• Cash and investments: ~$780M (runway into late 2028)
• Market cap: ~$8.2B
• 52-week range: ~$14.51 to ~$102.06

Spyre has no product revenue and posts steady losses funding R&D, so traditional earnings and valuation multiples do not apply (as of July 2026). Its roughly $8.2 billion market cap reflects expectations for its TL1A and IBD pipeline, not current cash flow. Investors weigh cash runway against clinical milestones rather than profits.

There are three common ways to get SYRE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so SYRE sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where SYRE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Spyre is a binary, catalyst-driven clinical-stage biotech whose story hinges on 2026-2027 trial data, not current financial results.

Whether SYRE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SYRE a buy?, and where the stock could go from here in the SYRE stock forecast.

For income investors, whether SYRE pays a dividend and how the payout looks is covered in does SYRE pay a dividend?